Pharmaceutical company wins $107.5 million jury verdict in patent dispute involving AstraZeneca's lung cancer treatment Tagrisso^®

Client(s) Puma Biotechnology, Inc.

Jones Day on behalf of a pharmaceutical company won a jury award of $107.5 million in damages after a five-day trial and less than three hours of jury deliberation. On May 17, 2024, the Delaware federal jury found for our client in a patent infringement dispute with AstraZeneca Pharmaceuticals LP and its affiliate over Tagrisso^®, a multibillion-dollar non-small cell lung cancer therapy. Jones Day proved that AstraZeneca induced infringement of U.S. Patent Nos. 10,603,314 and 10,596,162, directed to methods for the treatment of patients with gefitinib and/or erlotinib resistant non-small cell lung cancer. The jury also concluded that AstraZeneca failed to prove invalidity and awarded $107.5 million in damages to plaintiff as compensation for infringing sales of Tagrisso^® through December 2023. The case was brought by Puma Biotechnology, a licensee of Wyeth and its patents, and Wyeth LLC.

Puma Biotechnology, Inc. v. AstraZeneca Pharmaceuticals LP et al., No. 1-21-cv-01338 (D. Del.)